KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Finished Goods (2023 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Finished Goods for 3 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Finished Goods changed N/A year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, changed N/A, and an annual FY2024 reading of $903000.0, up 54.89% over the prior year.
  • Finished Goods was $1.4 million for Q3 2025 at Aurinia Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $3.7 million in Q1 2025 and bottomed at $583000.0 in Q4 2023.
  • Average Finished Goods over 3 years is $1.8 million, with a median of $1.4 million recorded in 2025.
  • Peak annual rise in Finished Goods hit 54.89% in 2024, while the deepest fall reached 54.89% in 2024.
  • Year by year, Finished Goods stood at $583000.0 in 2023, then skyrocketed by 54.89% to $903000.0 in 2024, then skyrocketed by 53.38% to $1.4 million in 2025.
  • Business Quant data shows Finished Goods for AUPH at $1.4 million in Q3 2025, $2.6 million in Q2 2025, and $3.7 million in Q1 2025.